The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.

ABSTRACT:

Background

Concerns about the immune reconstitution inflammatory syndrome (IRIS) remain a barrier to antiretroviral therapy (ART) initiation during antituberculosis treatment in co-infected patients.

Objective

To assess IRIS incidence, severity, and outcomes relative to the timing of ART initiation in patients with HIV-related tuberculosis.

Design

Randomized, open-label clinical trial. (ClinicalTrials.gov registration number: NCT00398996)

Setting

An outpatient clinic in Durban, South Africa.

Patients

642 patients co-infected with HIV and tuberculosis.

Measurements

In a secondary analysis of the SAPiT (Starting Antiretroviral Therapy at Three Points in Tuberculosis) trial, IRIS was assessed in patients randomly assigned to initiate ART within 4 wee

SUBMITTER: Naidoo K 

PROVIDER: S-EPMC3534856 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature